Theravance Biopharma, Inc.
Theravance Biopharma, Inc. (TBPH): 2 pipeline candidates · 2 upcoming catalysts · ~44 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
43.8 months
0% dilution
Lead: Approved
2 candidates
2 upcoming, next in ~562d
0 buys · 3 sells (180d)
A transparent, data-derived signal for Theravance Biopharma, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$849.6M
Cash
$288.9M
Quarterly Burn
$27.2M
Runway
43.8 mo
Revenue
$17.7M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| ampreloxetine | Phase 3 |
| yupelri | Approved |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
170
Total value held
$625.6M
| Holder | Shares | Value |
|---|---|---|
| weiss asset management lp | 7,457,060 | $121.0M |
| newtyn management, llc | 4,841,629 | $78.6M |
| blackrock, inc. | 4,296,290 | $69.7M |
| vanguard capital management llc | 3,567,506 | $57.9M |
| state street corp | 1,297,323 | $21.1M |
| two sigma investments, lp | 1,258,497 | $20.4M |
| geode capital management, llc | 1,137,462 | $18.5M |
| dimensional fund advisors lp | 983,615 | $16.0M |
| d. e. shaw & co., inc. | 954,042 | $15.5M |
| ubs group ag | 764,105 | $12.4M |
Showing top 10 of 170 institutional holders of Theravance Biopharma, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Theravance Biopharma, Inc.'s pipeline?
Theravance Biopharma, Inc. (TBPH) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Theravance Biopharma, Inc.'s lead drug candidate?
Theravance Biopharma, Inc.'s most advanced tracked candidate is ampreloxetine (Phase 3) for Symptomatic Neurogenic Orthostatic Hypotension.
What is Theravance Biopharma, Inc.'s next catalyst?
Theravance Biopharma, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Multi-center, Randomized Withdrawal and Long Term Extension Study of Ampreloxetine for th" — expected January 1, 2028.
What is Theravance Biopharma, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Theravance Biopharma, Inc. has approximately 43.8 months of cash runway.
What is Theravance Biopharma, Inc.'s market capitalization?
Theravance Biopharma, Inc.'s market capitalization is approximately $849.6M.
Get the full picture on Theravance Biopharma, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.